SCHEMBL14053150

SCHEMBL14053150

O=C(O)C(CO)Nc1cccnc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FDPS P14324 1/20 0.51
▸ NPC1 O15118 2/20 0.50
▸ RAB9A P51151 2/20 0.50
▸ PKM P14618 1/20 0.50
▸ CFTR P13569 1/20 0.50
▸ GOPC Q9HD26 1/20 0.50
▸ CYP1A2 P05177 1/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ CYP2D6 P10635 1/20 0.48
▸ CYP2C9 P11712 1/20 0.48
▸ CYP2C19 P33261 1/20 0.48
▸ NAMPT P43490 3/20 0.47
▸ EPHX2 P34913 1/20 0.47
▸ ALDH1A1 P00352 3/20 0.47
▸ LMNA P02545 2/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ GAA P10253 1/20 0.47
▸ KDM4E B2RXH2 2/20 0.46
▸ HIF1A Q16665 1/20 0.45
▸ NOTUM Q6P988 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14052936 1.00 FDPS (0.51) FDPSNPC1RAB9APKMCFTR
SCHEMBL30340371 0.86 NPC1 (0.50) FDPSNPC1RAB9APKMCFTR
SCHEMBL29416376 0.86 NPC1 (0.50) FDPSNPC1RAB9APKMCFTR
SCHEMBL3996687 0.83 CYP1A2 (0.62) FDPSNPC1RAB9APKMCFTR
SCHEMBL3488827 0.81 MME (0.45) RAB9ACYP3A4EPHX2ALDH1A1LMNA
SCHEMBL344918 0.81 MME (0.45) RAB9ACYP3A4EPHX2ALDH1A1LMNA
SCHEMBL344919 0.81 MME (0.45) RAB9ACYP3A4EPHX2ALDH1A1LMNA
SCHEMBL8581194 0.80 MMP2 (0.45) FDPSNPC1RAB9APKMCFTR
SCHEMBL31052770 0.80 FDPS (0.44) FDPSNPC1RAB9APKMCFTR
SCHEMBL30998137 0.80 FDPS (0.44) FDPSNPC1RAB9APKMCFTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170172957-A1 D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS ALLERGAN, INC. 2017-06-22 — — US disclosed
EP-2714029-B1 D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS ALLERGAN INC (US) 2017-04-12 — — EP disclosed
US-9415031-B2 D-serine transporter inhibitors as pharmaceutical compositions for the treatment of visual system disorders ALLERGAN, INC. (US) 2016-08-16 — — US disclosed
US-20140221453-A1 D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VISUAL SYSTEM DISORDERS ALLERGAN, INC. (US) 2014-08-07 — — US disclosed
US-8741955-B2 D-serine transporter inhibitors as pharmaceutical compositions for the treatment of central nervous system disorders ALLERGAN, INC. (US) 2014-06-03 — — US disclosed
US-8735451-B2 D-serine transporter inhibitors as pharmaceutical compositions for the treatment of visual system disorders ALLERGAN, INC. (US) 2014-05-27 — — US disclosed
US-20120329851-A1 D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS ALLERGAN, INC. 2012-12-27 — — US disclosed
WO-2012166533-A1 D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VISUAL SYSTEM DISORDERS ALLERGAN, INC. (US) 2012-12-06 — — WO disclosed
WO-2012166544-A1 D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS ALLERGAN, INC. (US) 2012-12-06 — — WO disclosed
US-20120302621-A1 D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VISUAL SYSTEM DISORDERS ALLERGAN, INC. 2012-11-29 — — US disclosed
Send feedback